Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zhongyuan Union Stem Cell Bio-Engineering Buys Zhicheng For RMB 800 Million

This article was originally published in PharmAsia News

Executive Summary

Zhongyuan Union Stem Cell Bio-Engineering said May 22 it would buy 100% of the equity of Shanghai Zhicheng Biotechnology for RMB 800 million ($129 million) using 70% paid by shares at RMB 24.5 a share and 30% by cash.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts